Liver transplantation: donor types, assessment, surgery and lifelong care

Liver transplantation replaces a diseased liver with a donor liver or a suitable portion of one. It is an option for selected people with severe liver disease or particular liver conditions, after a specialist assessment of benefit, risk and continuing care. It creates a new care pathway involving anti-rejection medicines and monitoring. Confidence is high in the need for transplant-team assessment; comparative outcomes and individual prognosis are not independently established in this guide.

Evidence summary

Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.

What liver transplantation means

The usual operation is called an orthotopic liver transplant: the donor organ is placed where the diseased liver was removed. A transplant is a treatment for a carefully assessed problem, rather than evidence that every underlying illness or future risk has disappeared. Operation overview.

The NHSBT suitability page includes selected people with decompensated cirrhosis, certain liver cancers associated with cirrhosis, or sudden acute liver failure. Some other conditions may be considered for severe symptoms or organ enlargement. These are reasons for specialist discussion, not a checklist that establishes a person’s eligibility. Who may be considered.

Useful questions at referral are: what problem is transplantation intended to solve, which alternatives remain, and what information is missing before the team can decide? Ask for the diagnosis in writing, including whether the concern is liver function, complications, cancer or a different condition.

Whole, split and living-donor liver grafts

A deceased donor’s liver may be transplanted whole or divided into suitable grafts for two recipients. A living donor gives a portion of their liver. Suitability depends on the donor, graft and recipient; the existence of a relative willing to donate does not establish a safe match. Whole and split organs; Living and deceased donation.

During surgery, the team reconnects blood vessels and the bile drainage pathway. The precise reconstruction can differ, including when the recipient’s bile duct cannot be used. These are operative decisions, not techniques a patient can select from a brief diagram. Blood supply and bile connections.

Keep the donor’s assessment separate from the recipient’s assessment. If living donation is being discussed, ask which team explains the donor’s risks and consent, and what happens if donation cannot proceed. This guide does not compare donor approaches by success rate or imply that one is best for everyone.

Assessment, waiting and organ offers

The liver and transplant teams must judge whether the expected benefit outweighs the operation and aftercare risks. Frailty, serious illnesses and practical difficulties with medicines can matter, but each requires an individual assessment. Discuss what is potentially treatable, what support is available and when the decision will be reviewed. Assessment context.

In the UK offering system, factors include blood group, disease severity, likely benefit and waiting time. The transplant centre reviews an offered organ against the recipient’s history before contacting them. Waiting time alone does not determine a person’s place. Other jurisdictions use their own systems. Organ offering.

Ask who to contact if health changes while waiting, how contact details are kept current, and what to bring if called. Avoid treating an average waiting time or online score as a promise. An offer may still be unsuitable after more information becomes available.

Nutrition, activity and supplements after transplantation

NHSBT describes continuing support with food, physical activity, smoking cessation and other health concerns. Recovery and restrictions differ; get the transplant team’s diet and activity advice rather than adopting a fixed exercise timetable. If alcohol contributed to the original liver disease, its advice is to avoid alcohol after transplantation. Health after transplantation.

Nutrition replacement for a documented need is different from claiming that a “liver cleanse” protects a graft. No fully financially screened supplement cure or anti-rejection replacement is established here. A product marketed as immune boosting does not answer the transplant-specific question of how it affects prescribed treatment.

NCCIH’s safety information warns that supplements can interact with medicines and that natural origin does not establish safety. Bring ingredients, quantities actually used and product packaging to the transplant pharmacist; include powders, teas and products bought online. Selected supplement safety context.

Expected goals, limits and informed consent

The aim is to improve the outlook of selected patients whose liver condition justifies transplantation. The NHSBT overview also says that not everyone feels better or lives longer and that serious surgical and medicine risks remain. Its displayed survival figures refer to 2019–2020 data, which this article does not apply as a current personal forecast. Benefits and limitations.

Ask how the team describes benefit for your diagnosis and which outcome matters: relief of a particular complication, function, cancer control or survival. A successful operation and the course of the underlying disease are related but distinct questions.

The organ offer discussion should explain significant donor health issues and possible disease transmission while protecting donor identity. Acceptance is a consent decision supported by the transplant team; another patient’s willingness to accept risk does not settle yours. Offer-specific consent.

Surgical complications and urgent warning signs

Potential problems include bleeding, infection, impaired graft function and bile duct complications. Risks arise during surgery and later; the operation is not the end of surveillance. Ask which warning signs concern the wound, graft, infection or medicines, and which number is staffed outside clinic hours. Risk overview.

Contact the transplant team promptly for new jaundice, abdominal pain, fever or shivering, vomiting or diarrhoea, severe headache, reduced urine or feeling substantially unwell. Some early problems are detected by clinic blood tests before obvious symptoms, so feeling well does not replace appointments. Warning signs and surveillance.

Severe chest pain, severe difficulty breathing, collapse or rapidly worsening illness needs emergency assessment through the local emergency service. Tell responders about the liver transplant and bring the medicine list if readily available. Do not delay urgent care while trying to identify the exact transplant complication at home.

Transplant medicines and important interactions

Anti-rejection medicines suppress the immune response to the graft. The centre selects and monitors the combination; side effects can involve infection, kidney function, blood sugar, blood counts, bone health and other issues. Different centres use different regimens. Blood medicine levels may form part of monitoring. Medicine and monitoring context.

St John’s wort can weaken cyclosporine, a medicine used to prevent rejection. This is a specific interaction warning, not proof that every herb interacts in the same way. Do not add it without transplant-team review or alter anti-rejection treatment to accommodate it. Cyclosporine interaction.

Before another clinician prescribes an antibiotic, pain medicine or other new treatment, make the transplant medicines visible. Ask the pharmacist to check the exact combination. If doses were missed or vomiting prevents medicine use, contact the transplant team for instructions; this article provides no catch-up or replacement-dose rule.

Who needs additional planning and support

Suitability and aftercare discussions should include other major illnesses, infection concerns, frailty, psychological difficulties and the ability to manage medicines. Present these as needs to assess and support, not moral tests or universal exclusion rules. Individual suitability discussion.

Ask how pregnancy intentions, childcare, housing, transport, language needs and help at home affect the care plan. For family planning, request a review of the actual medicines before trying to conceive; some regimens need specialist changes. Do not stop medicines or assume a general post-transplant waiting period establishes safety. Medicine review for family planning.

A named coordinator can help clarify which team handles liver disease, surgery, medicines and ongoing community care. If keeping appointments or obtaining medicines is becoming difficult, raise it early so the team can address the specific barrier.

Preparing for surgery and continuing care at home

The operation uses general anaesthesia and specialist monitoring. The team explains the planned surgery, blood products and lines, as well as any additional procedures needed for the recipient’s anatomy. The duration and recovery are not fixed by the operation’s name. Operative planning.

At discharge, get a written plan for medicines, wound care, food and drink, activity, pain management and follow-up. NHSBT directs recipients to the transplant team before using nonprescription pain medicines and stresses reporting missed doses. Ask when driving, work, exercise and travel can be reconsidered for your recovery. Home-care instructions.

Keep the transplant contact number accessible to the people helping you. Check which professional owns blood-test results and whether a local clinician and the transplant centre share the same medicine list. If two instructions conflict, ask the transplant team to reconcile them; do not choose a medicine pause or diet restriction by guessing.

Animal studies and experimental liver-preservation claims

A preserved organ, cell response or animal transplant result cannot establish a safe human alternative to liver transplantation or anti-rejection treatment. Studies of preservation machines, graft biology and immune tolerance may address different questions. A claim requires the relevant human recipients, comparator, meaningful outcomes, harms and financial chain.

No animal or in-vitro finding is used here to recommend an herbal graft-protection product, promise medicine-free transplantation or rank preservation devices. If offered research participation, ask which parts are established care, which are investigational and whether joining changes ordinary treatment or follow-up.

Funding and source roles

The selected NHSBT clinical originals provide attributed transplant-care context. Its own accounts and contact were checked separately. The overview identifies BTS collaboration; society financial originals were available only through indexed passages, with failed direct access disclosed. These gaps prevent certification of every contributor or supporting trial as independent.

NCCIH safety summaries and its historical appropriation/Gift Fund routes were also checked. No manufacturer-funded outcome is used as an independent efficacy conclusion. Institutional revenue, source role, financial tier and editorial credibility are separate judgements.

Frequently asked questions

Is a transplant a cure for every liver problem? No. It replaces the organ for a selected indication and creates continuing care needs; the underlying diagnosis and future risks require their own discussion. Treatment limits.

Does an offer mean the transplant must go ahead? No. The centre and recipient consider the specific organ and current health. Raise doubts promptly with the team. Offer consent.

Can I stop anti-rejection medicines when I feel well? Do not change them yourself. Some immunosuppression is needed for the lifetime of the graft; your team determines the regimen. Continuing medicines.

Can supplements replace monitoring? No replacement is established here. Clinic tests can identify problems before symptoms, while supplements need their own interaction review. Follow-up.

Are average waiting and survival figures personal predictions? No. Ask your team about your diagnosis, current health, matching system and the period represented by any statistic. Matching factors.

Sources and funding notes

Actual selected NHSBT originals and own2025–2026 accounts/contact read; clinical revision dates, full contributors and underlying trial chains unclosed. BTS collaboration is explicitly identified; official indexed corporate/partner context retained with direct-access failure. Old donor proportions, waiting averages and2019–2020 survival excluded. Actual NCCIH2019 supplement-safety andMay2025 StJohn’s-wort bodies, historical appropriation/Gift Fund originals read. General specialist education, no complete current eligibility, comparative drug/device benefit or personal regimen.

1. NHSBT liver-transplant information and BTS collaboration; clinical date unclosed — Definition and explicitly identified professional collaboration
2. NHSBT who may have a liver transplant; clinical date unclosed — Selected indications and individual assessment
3. NHSBT whole/split liver transplant; clinical date unclosed — Whole/split anatomy, no comparative success estimate
4. NHSBT deceased and living liver donation; clinical date unclosed — Living/deceased distinction, dated proportions excluded
5. NHSBT liver offering system; clinical date unclosed — Selected UK offering framework, no priority score
6. NHSBT accepting or declining an offered liver; clinical date unclosed — Donor risk and consent, no waiting-time promise
7. NHSBT orthotopic liver-transplant surgery; clinical date unclosed — Selected operative mechanism, no duration or risk rates
8. NHSBT liver-transplant benefits and risks; historical survival data excluded — Goals and harms; historical2019–2020 survival excluded
9. NHSBT liver-transplant medicines; clinical date unclosed — Ongoing medicine/monitoring safety, no regimen
10. NHSBT liver-transplant warning signs; clinical date unclosed — Warning signs and follow-up, no numeric threshold
11. NHSBT home care after liver transplantation; clinical date unclosed — Selected individualized home-care planning
12. NHSBT health after liver transplantation; clinical date unclosed — Lifestyle support; no fixed exercise or diet schedule
13. NCCIH supplement safety, January2019; selected safety context only — Selected2019 safety context, no efficacy
14. NCCIH St John’s wort, May2025; interaction context only — ActualMay2025 cyclosporine interaction context
15. NHSBT own 2025–2026 audited accounts, July 2026 — Separate current audited institutional routes
16. NHSBT original head-office contact — Separate actual institution location
17. BTS corporate-partnership original, indexed passages only; direct access failed — Explicit indexed-only corporate revenue context
18. BTS named partner original, indexed passages only; direct access failed — Explicit indexed-only named society-partner context
19. NCCIH actual appropriation history, through FY2024 — Historical public appropriation route only
20. NCCIH separate conditional/unconditional Gift Fund authority — Separate permitted gifts; complete receipts unclosed

Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.